CYTK [NASD]
Cytokinetics, Incorporated
Index- P/E- EPS (ttm)-2.59 Insider Own1.10% Shs Outstand85.73M Perf Week2.69%
Market Cap4.70B Forward P/E- EPS next Y-4.43 Insider Trans-22.96% Shs Float84.97M Perf Month30.83%
Income-215.90M PEG- EPS next Q-1.16 Inst Own- Short Float13.79% Perf Quarter31.44%
Sales151.20M P/S31.11 EPS this Y-42.00% Inst Trans1.43% Short Ratio8.34 Perf Half Y38.34%
Book/sh1.30 P/B39.08 EPS next Y1.60% ROA-26.20% Target Price64.17 Perf Year67.93%
Cash/sh6.33 P/C8.03 EPS next 5Y15.00% ROE-119.90% 52W Range29.10 - 54.74 Perf YTD11.45%
Dividend- P/FCF- EPS past 5Y-56.00% ROI-48.00% 52W High-8.79% Beta1.15
Dividend %- Quick Ratio9.00 Sales past 5Y-7.90% Gross Margin- 52W Low71.58% ATR2.72
Employees253 Current Ratio9.00 Sales Q/Q-82.50% Oper. Margin- RSI (14)58.91 Volatility3.58% 6.11%
OptionableYes Debt/Eq1.79 EPS Q/Q73.10% Profit Margin- Rel Volume0.30 Prev Close50.80
ShortableYes LT Debt/Eq1.78 EarningsAug 04 AMC Payout- Avg Volume1.41M Price49.93
Recom1.80 SMA207.28% SMA5012.88% SMA20026.50% Volume113,265 Change-1.71%
Jan-28-22Initiated Goldman Buy $74
Dec-22-21Initiated Oppenheimer Outperform $55
Dec-10-21Initiated JP Morgan Overweight $58
Oct-07-21Initiated Jefferies Buy $75
Mar-12-21Initiated Wolfe Research Outperform $50
Feb-18-21Initiated Barclays Overweight $28
Jan-20-21Reiterated H.C. Wainwright Buy $22 → $41
Oct-29-20Initiated Goldman Neutral $16
Jul-10-20Initiated Raymond James Strong Buy $39
May-05-20Initiated Mizuho Buy $31
Apr-09-20Upgrade Morgan Stanley Equal-Weight → Overweight $25
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-10-18Resumed Morgan Stanley Equal-Weight $10
Nov-22-17Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17Reiterated H.C. Wainwright Buy $26 → $17
Jul-31-17Initiated Morgan Stanley Overweight $24
Mar-08-17Initiated Rodman & Renshaw Buy $25
Feb-06-17Upgrade Needham Buy → Strong Buy $17 → $22
Dec-16-16Initiated Cantor Fitzgerald Overweight $21
Aug-05-22 08:16AM  
Aug-04-22 05:15PM  
04:00PM  
07:30AM  
Aug-01-22 04:00PM  
Jul-21-22 04:00PM  
Jul-07-22 08:18AM  
Jul-05-22 04:00PM  
Jul-01-22 03:35AM  
Jun-29-22 04:35PM  
Jun-24-22 08:44AM  
07:30AM  
Jun-22-22 09:14AM  
Jun-17-22 07:30AM  
Jun-16-22 07:30AM  
Jun-13-22 07:30AM  
Jun-03-22 04:00PM  
Jun-02-22 04:00PM  
Jun-01-22 04:00PM  
May-23-22 11:30AM  
May-18-22 07:30AM  
May-17-22 04:00PM  
07:30AM  
May-16-22 04:00PM  
May-10-22 06:15AM  
May-04-22 05:15PM  
04:00PM  
May-03-22 04:00PM  
May-02-22 04:01PM  
02:37PM  
04:11AM  
Apr-20-22 04:00PM  
Apr-08-22 07:30AM  
Apr-06-22 04:00PM  
Apr-03-22 09:45AM  
Apr-02-22 11:30AM  
Apr-01-22 04:00PM  
Mar-24-22 04:00PM  
Mar-08-22 04:00PM  
Mar-04-22 05:17AM  
Mar-02-22 07:30AM  
Mar-01-22 04:00PM  
Feb-28-22 07:30AM  
Feb-24-22 05:20PM  
04:00PM  
Feb-23-22 07:30AM  
Feb-17-22 03:02PM  
Feb-16-22 07:30AM  
Feb-15-22 07:30AM  
Feb-14-22 08:15PM  
Feb-11-22 01:00PM  
Feb-10-22 04:00PM  
Feb-07-22 06:38PM  
Feb-04-22 09:38AM  
07:30AM  
Feb-01-22 04:00PM  
01:42PM  
11:26AM  
07:30AM  
03:21AM  
Jan-31-22 10:00AM  
Jan-24-22 07:30AM  
Jan-10-22 05:00PM  
Jan-09-22 06:23AM  
Jan-07-22 08:07AM  
07:30AM  
Jan-03-22 04:00PM  
Dec-27-21 10:38PM  
Dec-23-21 10:32AM  
Dec-20-21 07:30AM  
Dec-18-21 02:38AM  
Dec-12-21 03:51PM  
Dec-10-21 10:21AM  
07:30AM  
Dec-09-21 07:30AM  
Dec-01-21 04:00PM  
Nov-30-21 04:00PM  
Nov-22-21 10:35AM  
Nov-15-21 04:00PM  
07:30AM  
Nov-08-21 04:00PM  
10:06AM  
Nov-06-21 09:27AM  
Nov-04-21 12:30AM  
Nov-03-21 05:15PM  
04:00PM  
Nov-01-21 04:00PM  
Oct-29-21 07:30AM  
Oct-27-21 03:03PM  
10:00AM  
Oct-21-21 04:00PM  
11:19AM  
Oct-20-21 04:00PM  
Oct-18-21 10:20AM  
Oct-11-21 10:20AM  
Oct-07-21 07:30AM  
Oct-01-21 04:00PM  
Sep-28-21 07:30AM  
Sep-23-21 04:00PM  
Sep-12-21 11:45AM  
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDDirectorAug 05Option Exercise8.7511,42899,99524,004Aug 08 04:01 PM
Kaye Edward M. MDDirectorAug 05Sale50.0011,428571,40012,576Aug 08 04:01 PM
Blum Robert IPresident & CEOAug 01Option Exercise7.9610,00079,600419,124Aug 03 04:11 PM
Blum Robert IPresident & CEOAug 01Sale41.2610,000412,600409,124Aug 03 04:11 PM
Blum Robert IPresident & CEOJul 18Option Exercise7.9610,00079,600419,472Jul 20 04:50 PM
Blum Robert IPresident & CEOJul 18Sale40.4910,000404,900409,472Jul 20 04:50 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 14Option Exercise9.6521,500207,475189,846Jul 14 05:24 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 14Sale43.4321,500933,745168,346Jul 14 05:24 PM
Blum Robert IPresident & CEOJul 06Option Exercise7.9610,00079,600419,472Jul 08 05:34 PM
Blum Robert IPresident & CEOJul 06Sale44.3810,000443,800409,472Jul 08 05:34 PM
Blum Robert IPresident & CEOJun 15Option Exercise7.9610,00079,600419,472Jun 17 04:08 PM
Blum Robert IPresident & CEOJun 15Sale39.4010,000394,000409,472Jun 17 04:08 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 09Option Exercise9.6521,500207,475189,846Jun 10 04:15 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 09Sale40.6221,500873,330168,346Jun 10 04:15 PM
Blum Robert IPresident & CEOJun 06Option Exercise7.9610,00079,600419,472Jun 08 04:08 PM
Blum Robert IPresident & CEOJun 06Sale41.2310,000412,300409,472Jun 08 04:08 PM
Blum Robert IPresident & CEOMay 16Option Exercise7.9610,00079,600419,124May 18 04:33 PM
Blum Robert IPresident & CEOMay 16Sale43.1110,000431,065409,124May 18 04:33 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 12Option Exercise9.6513,987134,975182,071May 12 05:52 PM
Malik Fady IbrahamEVP Research & DevelopmentMay 12Sale37.5413,987525,075168,084May 12 05:52 PM
Blum Robert IPresident & CEOMay 04Option Exercise7.9610,00079,600419,124May 06 04:31 PM
Blum Robert IPresident & CEOMay 04Sale39.4310,000394,321409,124May 06 04:31 PM
Blum Robert IPresident & CEOApr 20Option Exercise7.9610,00079,600419,124Apr 22 04:15 PM
Blum Robert IPresident & CEOApr 20Sale37.8910,000378,867409,124Apr 22 04:15 PM
Malik Fady IbrahamEVP Research & DevelopmentApr 07Option Exercise6.0023,148138,888191,232Apr 07 05:21 PM
Malik Fady IbrahamEVP Research & DevelopmentApr 07Sale42.5823,148985,755168,084Apr 07 05:21 PM
Jaw ChingSVP Finance & CFOApr 05Option Exercise12.1010,000121,00077,109Apr 06 07:12 PM
Jaw ChingSVP Finance & CFOApr 05Sale42.0010,000420,00067,109Apr 06 07:12 PM
Jaw ChingSVP Finance & CFOApr 04Option Exercise12.1015,000181,50082,109Apr 06 07:12 PM
Blum Robert IPresident & CEOApr 04Option Exercise7.9610,00079,600419,124Apr 06 07:11 PM
Jaw ChingSVP Finance & CFOApr 04Sale40.0015,000600,00067,109Apr 06 07:12 PM
Blum Robert IPresident & CEOApr 04Sale38.7810,000387,834409,124Apr 06 07:11 PM
Blum Robert IPresident & CEOMar 21Option Exercise7.9610,00079,600419,124Mar 23 05:30 PM
Blum Robert IPresident & CEOMar 21Sale36.0310,000360,342409,124Mar 23 05:30 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselMar 15Option Exercise10.6760,817648,636128,604Mar 15 07:34 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselMar 15Sale33.9625,196855,724103,408Mar 15 07:34 PM
Malik Fady IbrahamEVP Research & DevelopmentMar 10Option Exercise6.0026,852161,112194,936Mar 10 07:42 PM
Malik Fady IbrahamEVP Research & DevelopmentMar 10Sale37.8226,8521,015,462168,084Mar 10 07:42 PM
Jaw ChingSVP Finance & CFOMar 09Option Exercise12.1015,000181,50082,109Mar 09 06:27 PM
Jaw ChingSVP Finance & CFOMar 09Sale38.0015,000570,00067,109Mar 09 06:27 PM
Blum Robert IPresident & CEOMar 02Option Exercise7.9610,00079,600442,923Mar 04 05:03 PM
COSTA SANTO JDirectorMar 02Option Exercise10.6810,000106,80015,000Mar 02 06:59 PM
COSTA SANTO JDirectorMar 02Sale37.3510,000373,4775,000Mar 02 06:59 PM
Blum Robert IPresident & CEOMar 02Sale36.3110,000363,136432,923Mar 04 05:03 PM
HENDERSON JOHN TDirectorMar 01Option Exercise5.464,16622,74618,074Mar 01 07:48 PM
Blum Robert IPresident & CEOFeb 16Option Exercise7.9610,00079,600370,644Feb 18 05:37 PM
Blum Robert IPresident & CEOFeb 16Sale36.5010,000364,967360,644Feb 18 05:37 PM
Blum Robert IPresident & CEOFeb 07Option Exercise7.9610,00079,600370,644Feb 09 05:00 PM
Blum Robert IPresident & CEOFeb 07Sale33.8610,000338,594360,644Feb 09 05:00 PM
WIERENGA WENDALLDirectorDec 27Option Exercise5.464,16622,74610,931Dec 28 05:16 PM
SMITH SANDFORD DDirectorDec 27Option Exercise21.1128,290597,15026,765Dec 28 05:16 PM
WIERENGA WENDALLDirectorDec 27Sale44.374,166184,8546,765Dec 28 05:16 PM
SMITH SANDFORD DDirectorDec 27Sale45.7928,2901,295,3996,765Dec 28 05:16 PM
Kaye Edward M. MDDirectorDec 23Option Exercise7.6115,000114,15021,765Dec 23 07:11 PM
Kaye Edward M. MDDirectorDec 23Sale45.0015,000675,0006,765Dec 23 07:11 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 09Option Exercise6.3029,166183,746172,053Dec 09 07:02 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 09Sale36.4929,1661,064,288149,314Dec 09 07:02 PM
SMITH SANDFORD DDirectorNov 19Option Exercise13.1729,032382,24726,765Nov 19 06:16 PM
SMITH SANDFORD DDirectorNov 19Sale41.2129,0321,196,2756,765Nov 19 06:16 PM
Blum Robert IPresident & CEONov 12Option Exercise6.004,14324,858364,206Nov 12 05:23 PM
Blum Robert IPresident & CEONov 12Sale39.634,143164,172360,063Nov 12 05:23 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 11Sale39.562,00079,120148,878Nov 12 05:19 PM
Cragg DavidChief HR & Admin OfficerNov 09Option Exercise9.6545,000434,250163,223Nov 09 05:35 PM
Cragg DavidChief HR & Admin OfficerNov 09Sale41.7645,0001,879,209138,704Nov 09 05:35 PM
GAGE L PATRICKDirectorNov 08Option Exercise4.2526,468112,40051,234Nov 08 05:23 PM
GAGE L PATRICKDirectorNov 08Sale41.3326,4681,094,02328,932Nov 08 05:23 PM
HENDERSON JOHN TDirectorNov 05Option Exercise5.888,50349,99821,758Nov 05 06:33 PM
PARSHALL B LYNNEDirectorNov 05Option Exercise12.3430,996382,38125,000Nov 05 06:33 PM
PARSHALL B LYNNEDirectorNov 05Sale40.0030,9961,239,8405,000Nov 05 06:33 PM
HENDERSON JOHN TDirectorNov 05Sale40.008,503340,12013,255Nov 05 06:33 PM
Cragg DavidChief HR & Admin OfficerNov 01Option Exercise6.0025,000150,000157,029Nov 02 05:16 PM
Cragg DavidChief HR & Admin OfficerNov 01Sale34.8925,000872,240138,704Nov 02 05:16 PM
Blum Robert IPresident & CEOOct 29Option Exercise6.005,00030,000365,063Nov 02 05:16 PM
Blum Robert IPresident & CEOOct 29Sale35.805,000178,996360,063Nov 02 05:16 PM
PARSHALL B LYNNEDirectorOct 19Option Exercise6.6510,33268,67113,333Oct 20 06:56 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselOct 19Option Exercise7.0319,979140,45270,829Oct 20 06:57 PM
Jaw ChingSVP Finance & CFOOct 19Sale35.7335,6871,275,18653,064Oct 21 06:47 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselOct 19Sale35.7419,979713,97050,850Oct 20 06:57 PM
PARSHALL B LYNNEDirectorOct 19Sale35.7310,332369,2075,000Oct 20 06:56 PM
Blum Robert IPresident & CEOOct 14Option Exercise6.005,00030,000362,563Oct 15 04:37 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 14Sale37.732,00075,452150,878Oct 14 05:49 PM
Blum Robert IPresident & CEOOct 14Sale37.745,000188,712357,563Oct 15 04:37 PM
Cragg DavidChief HR & Admin OfficerOct 01Sale35.147,569265,990137,123Oct 01 04:34 PM
Blum Robert IPresident & CEOSep 30Option Exercise6.005,00030,000362,563Oct 01 04:28 PM
Blum Robert IPresident & CEOSep 30Sale34.015,000170,064357,563Oct 01 04:28 PM
Blum Robert IPresident & CEOSep 15Option Exercise6.245,00031,220361,628Sep 17 04:25 PM
Blum Robert IPresident & CEOSep 15Sale32.665,000163,316357,563Sep 17 04:25 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 09Sale31.432,00062,860152,878Sep 09 07:17 PM
Blum Robert IPresident & CEOSep 02Option Exercise6.305,00031,500362,563Sep 03 04:24 PM
Blum Robert IPresident & CEOSep 02Sale33.125,000165,577357,563Sep 03 04:24 PM
Cragg DavidChief HR & Admin OfficerSep 01Sale32.787,850257,311144,692Sep 02 04:08 PM